Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPyxis Oncology Inc

Pyxis Oncology Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.66 USD 0.05 ( 3.11%)
Last update at 2026-11-06T21:07:00Z
VOLUME
557578
Market Cap
277.75M

Momentum Score

…

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.62
Low
1.74
High
52 Week Price Range
1.03
Low
5.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.61
Dividend Yield
-
Revenue TTM
11.04M
Revenue Per Share
0.17
Gross Profit TTM
8.65M
Debt / Equity
0.35
ROE
-179.10%
Net Debt
3.25M
ROCE
-111.15%
Diluted EPS TTM
-1.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -78.23M -79.50M -73.79M -120.72M -75.97M
Net income -79.62M -77.33M -73.79M -117.95M -81.54M
Selling general administrative 22.19M 25.42M 32.61M 37.35M 18.66M
Selling and marketing expenses - - 1.78M - -
Gross profit 11.47M 15.67M -2.00M - -
Reconciled depreciation 4.51M 2.98M 1.43M 0.71M 0.65M
Ebit -78.23M -68.50M -73.79M -124.19M -69.72M
Ebitda -73.72M -65.51M -71.86M -123.48M -63.49M
Depreciation and amortization 4.51M 2.98M 1.93M 0.71M 6.23M
Non operating income net other - - - 2.76M -6.26M
Operating income -84.42M -89.46M -82.20M -123.48M -69.72M
Other operating expenses 98.28M 105.61M 82.20M 123.48M 69.72M
Interest expense - - - 2.76M 6.26M
Tax provision 1.39M -2.16M 0.00M - -
Interest income 3.61M 7.04M 6.91M 2.76M 0.02M
Net interest income 3.61M 7.04M 6.91M 2.76M 0.02M
Income tax expense 1.39M -2.16M 1.78M -2.76M 5.56M
Total revenue 13.86M 16.15M 0.00M 0.00M 0.00M
Total operating expenses 95.89M 105.13M 82.20M 123.48M 69.72M
Cost of revenue 2.39M 0.47M 2.00M - -
Total other income expense net 6.18M 9.96M 8.41M 2.76M -6.26M
Net income from continuing ops -79.62M -77.33M -94.29M -120.72M -75.97M
Net income applicable to common shares - - - -120.72M -75.97M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 91.52M 157.18M 173.73M 211.38M 280.02M
Intangible assets - 2.60M 24.31M - -
Other current assets 4.55M 5.51M 3.81M 5.85M 2.47M
Total liab 38.11M 36.43M 48.02M 50.55M 18.71M
Total stockholder equity 53.41M 120.75M 125.70M 160.82M 261.31M
Other current liab 8.55M 11.37M 12.97M 24.54M 0.27M
Common stock 0.06M 0.06M 0.04M 0.03M 0.03M
Capital stock 0.06M 0.06M 0.04M 0.03M 0.03M
Retained earnings -443.18M -363.56M -286.23M -212.44M -91.72M
Other assets - - - - 0.11M
Cash 15.42M 19.47M 11.14M 179.29M 274.74M
Total current liabilities 21.13M 17.68M 25.76M 31.63M 18.71M
Current deferred revenue - - 7.66M - 6.33M
Net debt 3.25M 0.73M 10.20M -160.37M -274.57M
Short term debt 1.69M 1.45M 1.23M - 0.17M
Short long term debt total 18.67M 20.20M 21.33M 18.92M 0.17M
Other stockholder equity 496.47M 484.08M 411.82M 373.23M 353.00M
Property plant equipment - - - 11.16M 1.01M
Total current assets 72.11M 132.44M 124.60M 186.61M 278.67M
Net tangible assets - - - 160.82M 261.31M
Short term investments 51.44M 107.46M 109.63M - -
Net receivables 0.70M - 0.02M 0.60M -
Inventory - - - 0.87M -
Accounts payable 10.88M 4.86M 3.90M 7.10M 11.95M
Accumulated other comprehensive income 0.05M 0.17M 0.06M - -280.02M
Common stock total equity - - - 0.03M 0.03M
Retained earnings total equity - - - -212.44M -91.72M
Non currrent assets other - - - 13.60M 0.11M
Non current assets total 19.41M 24.74M 49.12M 24.77M 1.35M
Capital lease obligations 18.67M 20.20M 21.33M 18.92M 0.17M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 58.87M 8.15M -116.94M -6.40M -0.05M
Change to liabilities - - - 3.62M 9.73M
Total cashflows from investing activities 58.86M 8.15M -104.85M -6.40M -0.59M
Total cash from financing activities 0.59M 59.33M 5.93M 0.18M 304.04M
Change to operating activities - - - - 2.03M
Net income -79.62M -77.33M -73.79M -120.72M -75.97M
Change in cash -4.05M 9.81M -169.63M -95.55M 268.13M
Begin period cash flow 20.95M 11.14M 180.76M 276.32M 8.19M
End period cash flow 16.89M 20.95M 11.14M 180.76M 276.32M
Total cash from operating activities -63.50M -57.67M -70.71M -89.33M -35.33M
Issuance of capital stock 0.00M 59.05M 6.12M 0.00M 303.88M
Depreciation 4.51M 2.98M 1.93M 0.71M 0.65M
Other cashflows from investing activities 165.87M 168.51M - - -
Sale purchase of stock - - -0.00M 0.18M 304.04M
Other cashflows from financing activities -0.15M 0.28M -0.19M -6.40M 151.75M
Change to netincome - - - 15.76M 32.67M
Capital expenditures 0.01M 0.24M 6.73M 6.40M 0.54M
Cash flows other operating - - - 11.29M -2.40M
Cash and cash equivalents changes - - - -95.55M 268.13M
Change in working capital 1.94M -11.82M -11.66M 4.50M 6.68M
Stock based compensation 11.80M 12.95M 16.95M 15.76M 6.44M
Other non cash items -2.14M 15.55M -4.13M 10.41M 20.60M
Free cash flow -63.51M -57.91M -77.44M -95.73M -35.87M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PYXS
Pyxis Oncology Inc		 0.05
3.11%		 1.66 - - 25.16 25.08 24.62 1.09
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Pyxis Oncology Inc

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

321 Harrison Avenue, Boston, MA, United States, 02118

617 453 3596

https://www.pyxisoncology.com

56

Name Title Year Born
Mr. John L. Flavin M.B.A., MBA, Ph.D. Co-Founder & Independent Chairman 1971
Dr. Lara S. Sullivan M.D., MBA CEO, Pres & Director NA
Ms. Pamela Yanchik Connealy M.B.A. Chief Financial Officer 1962
Dr. Jay M. Feingold M.D., Ph.D. Chief Medical Officer 1957
Mr. Jitendra Wadhane Chief Accounting Officer, Sr. VP of Fin. & Corp. Controller 1980
Dr. Balu N. Balasubramanian Ph.D. Interim Chief Technology Officer NA
Dr. Jan Pinkas Ph.D. Chief Scientific Officer NA
Ms. Martina Molsbergen B.S. Interim Chief Bus. Officer 1965
Dr. Charles T. Gombar Ph.D. Sr. VP of Portfolio & Program Management NA
Dr. Lara S. Sullivan M.D., MBA CEO, President & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…